Evidence map›Paper›PMID 42041699›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events.

Jana Burghaus-Zhang, Carsten Schulz, Egle Ramelyte, Joanna Mangana, Deniz Özistanbullu, Johannes Kleemann, Alexander Enk, Jessica C Hassel

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jana Burghaus-ZhangDepartment of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69115 Heidelberg, Germany.ORCID 0009-0000-9895-8265
Carsten SchulzDepartment of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69115 Heidelberg, Germany.
Egle RamelyteDepartment of Dermatology, University Hospital Zürich, 8006 Zürich, Switzerland.ORCID 0000-0001-8262-8608
Joanna ManganaDepartment of Dermatology, University Hospital Zürich, 8006 Zürich, Switzerland.
Deniz ÖzistanbulluDepartment of Dermatology, Johann Wolfgang Goethe University, 60629 Frankfurt am Main, Germany.
Johannes KleemannDepartment of Dermatology, Johann Wolfgang Goethe University, 60629 Frankfurt am Main, Germany.
Alexander EnkDepartment of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69115 Heidelberg, Germany.
Jessica C HasselDepartment of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69115 Heidelberg, Germany.ORCID 0000-0001-7575-6230

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProgrammed cell death protein (ligand) 1 (PD-(L)1) inhibitors are well established in the treatment of dermatological tumors. Mostly, they are well tolerated, but in about 9-21% of patients, grade 3/4 immune-related adverse events (irAEs) occur. As treatment options are limited, it is of interest to determine whether readministration of another or the same PD-(L)1 inhibitor is safe.

methodsThis is a multicenter, retrospective study on patients with metastasized dermatological tumors who were retreated with either the same or a different PD-(L)1 inhibitor after the development of irAEs. The study was conducted at centers in Heidelberg, Zurich, and Frankfurt.

results22 patients were included between April 2020 and December 2022 with a median age of 71 years. A total of 13 (59%) patients were re-exposed with the same antibody and nine (41%) received a different PD-(L)1 inhibitor. Six (46%) of the patients who were re-exposed to the same antibody had an irAE, of which 67% were identical with the first. In patients receiving a different PD-(L)1 inhibitor, four (44%) developed an irAE, of which 75% were identical with the first.

conclusionsBoth an intraclass switch of PD-(L)1 inhibitor treatment and re-exposure with the same antibody after an irAE can be considered as options with a fair chance of improving therapy tolerance.

Indexed as

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorSkin NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorimmune-related adverse eventsimmunotherapyskin cancer

Identifiers

PMID42041699
PMCPMC13114345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.